Androgen insensitivity syndrome — an X-linked disorder caused by inactivating mutations in the AR gene encoding the androgen receptor protein, an intracellular nuclear receptor that mediates the biological effects of androgens (testosterone and dihydrotestosterone) in all target tissues — encompasses a spectrum of presentations whose severity correlates with the degree of residual androgen receptor function: complete androgen insensitivity syndrome (CAIS), in which the androgen receptor is completely non-functional, occurs in approximately 1 in 20,000 live births assigned male at birth and produces a striking clinical phenotype in which 46,XY individuals with functioning testes secreting testosterone in the high male range develop a completely female external phenotype because peripheral androgen receptor function is entirely absent — the testes secrete testosterone (which cannot act on AR), estradiol (via aromatization of testosterone in peripheral tissues), and anti-Müllerian hormone (AMH), resulting in absent Müllerian-derived internal structures (no uterus, no fallopian tubes, no upper vagina — AMH suppresses them), absent Wolffian-derived male internal structures (testosterone cannot virilize Wolffian ducts without AR function), typically short or blind-ending vagina, intra-abdominal or inguinal testes, and at puberty, breast development and feminization from estradiol with absent pubic and axillary hair from androgen insensitivity; partial androgen insensitivity syndrome (PAIS), in which the androgen receptor retains partial function, produces variable ambiguous genitalia ranging from predominantly female with clitoromegaly (Quigley grade 3–4), through ambiguous to predominantly male with hypospadias, micropenis, or gynecomastia (Quigley grade 5–6) — PAIS management, gender of rearing, and sex steroid replacement are individualized based on phenotype, family preference, and emerging patient gender expression; management of CAIS centers on gender identity support, gonadal management decisions (gonads retained through adolescence for feminizing puberty and then gonadectomy post-puberty versus early gonadectomy — the evidence supporting deferring gonadectomy until the individual can participate in the decision), HRT after gonadectomy, bone density surveillance, psychological and peer support, and vaginal dilation or surgical vaginoplasty coordination if needed; management of PAIS is individualized and may include sex steroid supplementation in males, genital reconstructive surgery, and gender identity support regardless of gender of rearing.
Androgen insensitivity syndrome technology platforms — encompassing the pediatric and adult endocrinology scheduling and EHR platforms where specialist physicians coordinate gonadal management decisions, hormone monitoring, and HRT for CAIS and PAIS across the pediatric, adolescent, and adult life stages, the gonadal tumor surveillance imaging scheduling platforms managing the MRI and ultrasound intervals that document germ cell tumor risk in retained gonads, the hormone monitoring laboratory platforms measuring testosterone, LH, estradiol, and AMH confirming the CAIS biochemical profile and HRT adequacy, the bone density DXA surveillance platforms tracking osteoporosis risk from sex hormone deficiency after gonadectomy or inadequate HRT, the psychological wellbeing assessment platforms coordinating gender identity support, body image counseling, and peer network referrals, the HRT adherence tracking platforms confirming that post-gonadectomy estrogen replacement is maintained at doses adequate to protect bone and cardiovascular health, the vaginal dilation therapy adherence and coordination platforms managing the non-surgical approach to vaginal lengthening in CAIS, the multidisciplinary DSD team coordination portals connecting endocrinology, gynecology, psychology, and genetics for joint decision-making, and the genetic counseling documentation platforms managing the X-linked inheritance cascade with affected individuals' mothers and maternal female relatives — must maintain the availability and performance standards required by the gonadal tumor surveillance intervals, the HRT adherence monitoring precision, the bone density protection obligation, and the psychological wellbeing coordination complexity that define modern AIS care. This guide explains why AIS tech platforms need dedicated monitoring, what components to monitor, and how to build a monitoring strategy matched to the hormone monitoring, gonadal tumor surveillance, HRT adherence tracking, bone density protection, and psychosocial care coordination requirements of complete and partial androgen insensitivity syndrome.
Why AIS Tech Platforms Require Specialized Monitoring Attention
AIS management is defined by several interconnected challenges that make coordinated platform availability a direct patient care determinant: the gonadal tumor surveillance imperative — retained gonads in CAIS carry a lifetime germ cell tumor risk estimated at approximately 3–4% (predominantly gonadoblastoma), with the absolute risk rising with age and informing the timing of elective gonadectomy; imaging surveillance intervals (annual MRI or ultrasound) must be scheduled without gap, results reviewed, and any suspicious lesion escalated promptly to oncologic evaluation; the HRT adherence monitoring obligation — after gonadectomy, complete androgen and estrogen deficiency results unless exogenous estrogen is provided; inadequate HRT post-gonadectomy causes premature surgical menopause symptoms, accelerated bone loss, cardiovascular risk, and significant quality-of-life impairment; HRT adherence tracking and estradiol level monitoring are the primary tools for confirming replacement adequacy; the bone density protection requirement — sex hormone deficiency after gonadectomy (whether from inadequate HRT or delayed gonadectomy without HRT) progressively depletes bone mineral density, increasing fracture risk in individuals who may live 50–60 years post-gonadectomy; DXA surveillance documents bone health and guides HRT dose optimization; the psychological wellbeing complexity — the diagnosis of AIS involves disclosure of karyotypic sex, absent uterus/ovaries, retained gonads, and infertility — information that must be disclosed in a developmentally appropriate, patient-centered way with psychological support and peer network access; gender identity development in PAIS adds a further layer of individuation requiring specialized support; and the genetic counseling cascade — X-linked AR mutations mean that the patient's mother and maternal female relatives are obligate or possible carriers who may bear affected children.
Gonadal tumor surveillance platforms are the primary cancer risk management tool in CAIS. Annual MRI or ultrasound of retained gonads documents germ cell tumor risk and any suspicious lesion requiring oncologic evaluation. Monitor gonadal surveillance scheduling and imaging platforms at 1-minute intervals during clinical hours.
HRT adherence and estradiol monitoring platforms protect bone and cardiovascular health after gonadectomy. Post-gonadectomy estrogen replacement adequacy is documented by serum estradiol in the physiological female range and FSH suppression. Monitor HRT tracking platforms at 1-minute intervals during clinical hours.
Bone density DXA surveillance platforms track the long-term skeletal consequence of sex hormone management. Annual or biennial DXA monitors the effect of gonadectomy timing and HRT adequacy on lumbar spine and femoral neck bone mineral density. Monitor bone density platforms at 1-minute intervals during clinical hours.
Psychological wellbeing assessment platforms are integral to AIS care. Disclosure support, body image counseling, gender identity support, and peer network coordination are clinical care components in AIS — not supplementary services. Monitor psychological wellbeing platforms at 1-minute intervals during clinical hours.
DSD multi-disciplinary coordination portals manage complex care decisions. Gonadectomy timing, vaginal dilation or vaginoplasty coordination, HRT initiation, and genetic counseling require joint decision-making across endocrinology, gynecology, psychology, and genetics. Monitor DSD coordination platforms at 1-minute intervals during clinic hours.
What to Monitor on an AIS Tech Platform
Testosterone, LH, and AMH Monitoring (CAIS Biochemical Profile)
Monitor serum testosterone result records (testosterone in the high-normal male range in CAIS — typically 300–700 ng/dL — despite complete female phenotype; testosterone measurement confirms testicular androgen production unimpeded by absent AR function; testosterone below the expected male range post-puberty indicating testicular dysfunction or medication effect), LH result records (LH elevated above the normal male range — typically 10–30 IU/L — reflecting the absence of androgen receptor-mediated negative feedback on the hypothalamic-pituitary axis in CAIS; LH in the castrate range post-gonadectomy confirming gonadal removal), estradiol result records (estradiol in the mid-follicular female range from peripheral aromatization of testicular testosterone — feminizing puberty in CAIS explained by estradiol acting on estrogen receptor in the absence of AR-mediated androgen effects; post-gonadectomy estradiol on HRT confirming replacement adequacy), AMH result records (AMH detectable from retained testes — confirms testicular tissue presence; AMH undetectable post-gonadectomy confirming complete gonadal removal), and follicle-stimulating hormone records (FSH elevated in CAIS from absence of inhibin feedback — FSH and LH in the castrate range post-gonadectomy confirming complete gonadectomy) at 1-minute intervals during clinical hours. Alert immediately — hormone monitoring laboratory platform failures preventing testosterone and LH results from being processed for a 16-year-old with CAIS whose endocrinologist is reviewing the diagnostic biochemical profile at the time of disclosure preparation — result delay disrupts the carefully timed disclosure process coordinated with the psychology team.
Gonadal Tumor Surveillance: MRI and Ultrasound Scheduling
Monitor gonadal surveillance imaging scheduling records (annual MRI or ultrasound of retained gonads — intra-abdominal or inguinal gonad location confirmation, surveillance interval documentation, imaging appointment booked without scheduling gap), gonadal imaging result records (MRI characteristics — gonadal size, echogenicity, nodule detection; any lesion above 1 cm or with irregular margins triggering oncologic evaluation), germ cell tumor histology records (for patients who have undergone gonadectomy — histologic review of excised gonads for gonadoblastoma, dysgerminoma, or other germ cell neoplasia; management implications of positive findings including oncologic staging and treatment), and oncologic referral records (timely referral to gynecologic oncology for any suspicious gonadal lesion identified on surveillance imaging — referral date, evaluation date, treatment decision) at 1-minute intervals during clinical hours. Alert immediately — gonadal tumor surveillance scheduling platform failures leaving a 23-year-old with CAIS without a booked annual gonadal MRI for 18 months — extending the surveillance interval beyond the intended annual schedule and increasing the window during which an early germ cell lesion could progress undetected.
HRT Adherence and Estradiol Monitoring After Gonadectomy
Monitor estrogen replacement prescription and dispensing records (transdermal estradiol patch — typical doses 50–100 µg/24 hours in adults; oral estradiol 1–2 mg/day; subcutaneous estradiol pellet — prescription validity, dispensing frequency confirming adherence, HRT regimen continuity), serum estradiol result records (post-gonadectomy estradiol on HRT — target mid-follicular female range 50–200 pg/mL; estradiol below 30 pg/mL indicating HRT under-replacement causing bone loss acceleration and surgical menopause symptoms), FSH result records (FSH suppression below 15 IU/L on adequate estrogen replacement — FSH elevation above 25 IU/L indicating estrogen under-replacement with hypothalamic-pituitary feedback break-through), menopause symptom documentation records (hot flashes, night sweats, vaginal dryness, mood changes, and sleep disruption — symptom severity documenting the clinical impact of HRT adequacy or inadequacy), and HRT formulation adjustment records (dose increase for inadequate estradiol levels or breakthrough menopausal symptoms; formulation change for adherence improvement) at 1-minute intervals during clinical hours.
Bone Density DXA Surveillance
Monitor DXA bone mineral density records (lumbar spine L1–L4 and femoral neck T-score and Z-score — Z-score below −2.0 confirming low bone density for age, requiring HRT dose optimization and calcium/vitamin D supplementation review; T-score below −2.5 in adults confirming osteoporosis, requiring fracture risk stratification), calcium and vitamin D supplementation records (elemental calcium 1000–1200 mg/day and vitamin D 1000–2000 IU/day — dosing, adherence, and serum 25-OH vitamin D level above 30 ng/mL), fracture history records (vertebral and peripheral fractures documenting the clinical consequence of inadequate bone mineral density protection), and DXA surveillance interval records (every 2 years in adults post-gonadectomy on stable HRT; annually if bone density is declining or HRT adherence is poor) at 1-minute intervals during clinical hours.
Psychological Wellbeing Assessments and Disclosure Support
Monitor psychological wellbeing assessment records (validated quality-of-life instruments — FSFI for sexual function, HADS or PHQ-9 for anxiety and depression, AIS-specific QoL instruments — administered at annual visits), disclosure counseling records (developmentally appropriate disclosure process documentation — when, what, and how the AIS diagnosis including karyotype and gonadal anatomy was disclosed, by whom, with what psychological support, patient reaction and follow-up plan), body image assessment records (body satisfaction, fertility acceptance, physical self-concept documentation in clinical notes), gender identity records (gender identity development documentation — particularly in PAIS where gender of rearing may diverge from gender identity expression), peer support referral records (AIS support group referral — AIS-DSD Support Group, AISDSD.org, or local peer networks — referral date and uptake documentation), and mental health referral records (referral to psychologist, psychiatrist, or counselor for anxiety, depression, body dysmorphia, or adjustment difficulties identified on screening) at 1-minute intervals during clinical hours.
Vaginal Dilation Therapy and Vaginoplasty Coordination
Monitor vaginal dilation therapy records (non-surgical progressive vaginal dilation initiated by the patient using dilators of increasing caliber — technique taught by trained nurse specialist or physiotherapist; dilation frequency and duration documented; vaginal length and caliber achieved confirmed at follow-up), vaginal length assessment records (clinical or ultrasound vaginal length documentation at diagnosis and at dilation follow-up visits — typical CAIS vaginal blind pouch 4–8 cm at presentation, functional length >8–9 cm the goal of dilation therapy), vaginoplasty referral records (for patients who do not achieve adequate vaginal length with dilation — referral to specialist gynecologic surgeon for surgical vaginoplasty, timing, technique documentation, post-operative dilation protocol), and sexual function counseling records (counseling regarding CAIS-related sexual anatomy, dilation therapy goals, sexual function expectations, and relationship communication support) at 1-minute intervals during clinical hours.
Gender Identity and Dysphoria Support in PAIS
Monitor gender identity expression records (gender identity documentation for individuals with PAIS raised in any gender — recognition that gender identity in PAIS may not align with gender of rearing; referral to gender-affirming care when gender dysphoria is identified), gender-affirming care coordination records (referral to gender identity clinic, endocrinology for cross-sex hormone therapy, and surgery coordination when requested by the individual), psychological support records (counseling specifically addressing PAIS phenotype, gender of rearing history, and the individual's own gender identity experience), and legal name and gender marker documentation records (legal gender marker change support where applicable — documentation coordinated between the care team and social work) at 1-minute intervals during clinical hours.
Genetic Counseling and AR Carrier Documentation
Monitor AR molecular genetic testing records (gene sequencing confirming causative AR mutation — mutation type correlates with CAIS versus PAIS spectrum; X-linked inheritance pattern documentation), maternal carrier testing records (patient's mother — obligate carrier unless de novo mutation; carrier testing by AR gene sequencing; cascade testing offered to maternal female relatives), prenatal diagnosis records (for carrier mothers seeking prenatal testing — CVS or amniocentesis for fetal sex determination and AR mutation confirmation; reproductive options counseling), and family disclosure records (counseling regarding X-linked inheritance implications for maternal relatives who may bear affected children — patient consent for information sharing to relatives) at 1-minute intervals during clinical hours.
Authentication and Clinical Identity
Monitor authentication at 1-minute intervals, 24/7. AIS management coordinates across pediatric and adult endocrinology (hormone monitoring and HRT), gynecology (gonadectomy and vaginoplasty), gynecologic oncology (germ cell tumor surveillance and management), radiology (gonadal MRI/ultrasound and DXA), psychology (disclosure support, body image, gender identity), genetics (AR molecular analysis and carrier cascade testing), physical therapy (vaginal dilation training), pharmacy (HRT prescription and dispensing), and gender-affirming care programs (for individuals with PAIS) — authentication failures disrupt every team member required to execute the gonadal tumor surveillance, HRT adherence monitoring, bone density protection, and psychosocial care coordination that define AIS management.
SSL Certificates
Monitor SSL certificate expiry across all endocrinology scheduling portals, hormone monitoring laboratory platforms, gonadal tumor surveillance imaging systems, HRT tracking platforms, bone density surveillance platforms, and psychological wellbeing assessment systems. Certificate errors disrupt the coordinated multi-disciplinary workflows that are the clinical foundation of AIS care.
HIPAA and AIS Patient Privacy Considerations
AIS technology platforms handle PHI of exceptional sensitivity — including AR molecular genetic testing results (X-linked, with maternal carrier implications and GINA-protected genetic information), karyotype documentation confirming 46,XY chromosomal constitution in individuals with female phenotype (psychosocially sensitive, requiring patient-controlled disclosure with explicit consent-based access controls), gonadal anatomy documentation (intra-abdominal or inguinal testes in individuals with female gender identity — highly sensitive), gonadectomy surgical and pathology records (germ cell tumor findings requiring oncologic coordination), gender identity and gender expression records (particularly in PAIS — gender identity information requiring the highest level of privacy protection), vaginal dilation and sexual function records, and psychological wellbeing and mental health records.
The intersection of karyotypic disclosure, gonadal anatomy, gender identity, sexual function, fertility, and inherited genetic information in AIS records demands role-based access controls, patient-directed disclosure authorization, audit logging, and minimum necessary disclosure practices that center patient autonomy at every stage of care — from the pediatric disclosure process through adult HRT and tumor surveillance management.
Alerting Strategy for AIS Tech Platforms
Immediate clinical-hours alerting for gonadal tumor surveillance scheduling: Annual MRI or ultrasound scheduling without gap — the primary cancer risk management tool in CAIS. A missed surveillance year is an unacceptable gap in germ cell tumor risk management.
Immediate clinical-hours alerting for HRT monitoring platforms: Estradiol and FSH confirming post-gonadectomy replacement adequacy — the primary bone and cardiovascular health protection tool.
Immediate clinical-hours alerting for bone density DXA surveillance: DXA result review and calcium/vitamin D tracking confirming long-term skeletal protection.
Immediate clinic-hours alerting for DSD multi-disciplinary coordination portals: Gonadectomy planning, vaginoplasty coordination, psychological support, and genetics for joint decision-making.
Immediate clinic-hours alerting for psychological wellbeing assessment platforms: Disclosure support, body image, gender identity, and peer network coordination — clinical care, not supplementary services.
Sustained-failure alert (10–15 minutes): Patient registry, AR molecular genetic testing, maternal carrier cascade testing platforms, and long-term adult surveillance administrative systems.
30-day advance warning: SSL certificates across all domains, prioritizing gonadal tumor surveillance imaging platforms and HRT monitoring systems.
Vigilmon's multi-region monitoring confirms AIS platform availability from the geographies where DSD programs, gynecologic oncology centers, endocrinology practices, and psychology services that provide specialist AIS care concentrate.
Status Page for AIS Care Team Communication
A real-time status page gives endocrinologists monitoring hormone profiles and HRT adherence, gynecologists scheduling gonadectomy and vaginoplasty coordination, gynecologic oncologists reviewing tumor surveillance results, radiologists performing gonadal MRI/ultrasound and DXA studies, psychologists providing disclosure support and gender identity counseling, genetics counselors managing AR cascade testing, pharmacists dispensing HRT, and physical therapists coordinating vaginal dilation immediate platform visibility.
Include the status page URL in multi-disciplinary DSD team clinic coordination workflows, HRT adherence reminder systems, and gonadal tumor surveillance scheduling protocols.
Vigilmon Setup for AIS Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Authentication | 1 min | Slack + PagerDuty (24/7) | | Gonadal tumor surveillance scheduling (MRI/ultrasound annual interval) | 1 min | Slack + PagerDuty (clinical hours) | | Gonadal imaging results platform | 1 min | Slack + PagerDuty (clinical hours) | | Serum testosterone monitoring (CAIS biochemical profile) | 1 min | Slack + PagerDuty (clinical hours) | | LH and FSH monitoring | 1 min | Slack + PagerDuty (clinical hours) | | Estradiol monitoring (post-gonadectomy HRT adequacy) | 1 min | Slack + PagerDuty (clinical hours) | | AMH monitoring | 1 min | Slack + PagerDuty (clinical hours) | | HRT prescription and adherence tracking | 1 min | Slack + PagerDuty (clinical hours) | | Bone density DXA surveillance | 1 min | Slack + PagerDuty (clinical hours) | | DSD multi-disciplinary coordination portal | 1 min | Slack + PagerDuty (clinic hours) | | Psychological wellbeing assessment platform | 1 min | Slack + PagerDuty (clinic hours) | | Vaginal dilation therapy tracking | 1 min | Slack + PagerDuty (clinic hours) | | Vaginoplasty coordination and surgical planning | 2 min | Slack + PagerDuty (clinic hours) | | Gender identity and gender-affirming care coordination (PAIS) | 2 min | Slack + PagerDuty (clinic hours) | | AR molecular genetic testing platform | 2 min | Slack (business hours) | | Maternal carrier cascade testing | 2 min | Slack (business hours) | | Patient registry | 2 min | Slack (business hours) | | SSL: all domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add authentication endpoints at 1-minute intervals with 24/7 alerting
- Configure gonadal tumor surveillance scheduling with immediate clinical-hours alerting — annual MRI/ultrasound without scheduling gap is the primary cancer risk management obligation in CAIS
- Add gonadal imaging results platform with immediate clinical-hours alerting
- Configure testosterone, LH, FSH, and AMH monitoring with immediate clinical-hours alerting
- Add estradiol monitoring for post-gonadectomy HRT adequacy with immediate clinical-hours alerting
- Configure HRT prescription and adherence tracking with immediate clinical-hours alerting
- Add bone density DXA surveillance with immediate clinical-hours alerting
- Configure DSD multi-disciplinary coordination portal with immediate clinic-hours alerting
- Add psychological wellbeing assessment platform with immediate clinic-hours alerting
- Configure vaginal dilation therapy tracking with immediate clinic-hours alerting
- Add vaginoplasty coordination and surgical planning with sustained-failure alerting
- Configure gender identity and gender-affirming care coordination (PAIS) with sustained-failure alerting
- Add AR molecular genetic testing platform with sustained-failure alerting
- Configure maternal carrier cascade testing platforms with sustained-failure alerting
- Enable SSL certificate monitoring across all platforms, prioritizing gonadal tumor surveillance imaging and HRT monitoring systems
- Add the status page URL to DSD multi-disciplinary clinic coordination workflows and HRT adherence reminder systems
Conclusion
Androgen insensitivity syndrome technology platforms are embedded in clinical decisions where gonadal tumor surveillance scheduling platform availability for a 25-year-old with CAIS who has retained her intra-abdominal gonads — confirmed at the last visit by MRI, with no suspicious lesions identified 18 months ago — requires that this year's annual gonadal MRI appointment be booked without a scheduling gap, because the germ cell tumor risk accumulates with each year of retained gonadal tissue and an 18-month surveillance interval converts a 3–4% lifetime risk into an unmonitored window during which an early gonadoblastoma or dysgerminoma could emerge, grow, and potentially disseminate before the next imaging study detects it — and cannot be disrupted by scheduling platform failures that leave the annual gonadal MRI unbooked for 6 months past the intended anniversary; where HRT monitoring platform availability when the endocrinologist reviews the 6-month post-gonadectomy estradiol level for a 22-year-old with CAIS — estradiol 18 pg/mL, far below the target physiological female range, FSH 68 IU/L confirming breakthrough hypothalamic-pituitary response to estrogen under-replacement — requires an immediate HRT dose increase to protect bone mineral density in the decades ahead, because the DXA at gonadectomy already showed a lumbar Z-score of −1.4, and 6 months of estradiol deficiency have already accelerated the bone loss trajectory — cannot be disrupted by laboratory platform failures that delay the estradiol result and the dose adjustment that stands between this 22-year-old and progressive osteoporosis; and where psychological wellbeing platform availability when the 17-year-old with CAIS who received her first full disclosure of her diagnosis — including karyotype, absent uterus, retained intra-abdominal gonads, and lifetime infertility — 8 weeks ago needs her scheduled psychology follow-up appointment to process the identity, grief, and relationship implications of that disclosure — cannot be disrupted by scheduling system failures that leave her without the psychological support appointment that was explicitly planned as part of the disclosure protocol. A gonadal tumor surveillance platform with scheduling gaps that allow a germ cell lesion to progress undetected, an HRT monitoring system that cannot deliver the estradiol result that would prompt a dose increase protecting 50 years of bone health, a psychological wellbeing platform unavailable when a teenager needs post-disclosure support — these are not IT incidents. They are clinical disruptions in the management of a condition whose germ cell tumor surveillance obligation, HRT-dependent bone protection, disclosure psychological complexity, and gender identity individuation in PAIS make every monitoring platform a direct participant in the lifelong physical and psychological health of individuals whose androgen receptor mutation affects every facet of their biological development, medical management, and personal identity.
Uptime monitoring gives AIS tech teams the detection capability to identify failures within seconds, trigger immediate clinical downtime procedures, and demonstrate to DSD programs, gynecologic oncology centers, endocrinology practices, psychology services, and compliance auditors that platform operational reliability matches the gonadal tumor surveillance urgency, HRT adherence monitoring precision, bone density protection obligation, and psychosocial care coordination complexity of modern AIS management.
Start monitoring your AIS care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and webhook alerts. No agent required. No credit card.
Tags: #monitoring #androgen #insensitivity #syndrome #AIS #CAIS #PAIS #AR #46XY #DSD #gonadectomy #HRT #estrogen #testosterone #gonads #germ #cell #tumor #gonadoblastoma #bonedensity #osteoporosis #disclosure #genderidentity #psychologicalsupport #vaginaldilation #vaginoplasty #genetic #carrier #pediatric #endocrinology #gynecology #HIPAA #healthtech #digitalhealth #uptime #sre